Yeon Sue Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yeon Sue Jang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Baek Gil Kim
Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications - Hyun Ho Han
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
2 shared publications - Hyung Ho Lee
Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea
2 shared publications - Jinsoo Chung
Department of Urology, National Cancer Center, Goyang 10408, Republic of Korea
2 shared publications - Mingyu Kim
Center for Urologic Cancer, National Cancer Center, 323, Ilsan-Ro, Ilsandong-Gu, Goyang-Si 10408, Gyeonggi-Do, Republic of Korea
2 shared publications - Nam Hoon Cho
Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 1 October 2024
- Published by MDPI AG in Preprints.org
Exploring the Therapeutic Potential of Nicotinamide‐N‐Methyltransferase in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is a highly aggressive subtype of renal cancer, often associated with poor prognosis and high mortality rates. In this study, we identified Nicotinamide N-methyltransferase (NNMT) as a key gene involved in the pathogenesis of ccRCC through RNA sequencing analysis of tumor and normal tissues from 14 patients. NNMT was among the top five upregulated genes, and its high expression was significantly correlated with reduced overall, progression-free, and disease-specific survival in patients, as well as advanced pathological stages and higher histologic grades. Gene ontology (GO) enrichment analysis revealed NNMT's role in biological processes such as signal transduction and immune response. Immune cell infiltration analysis indicated that high NNMT expression was associated with increased infiltration of activated NK cells and macrophages, while low expression correlated with a higher presence of regulatory T cells. Functional studies using siRNA-mediated NNMT knockdown in ccRCC cell lines demonstrated a significant reduction in cell proliferation, with further analysis revealing altered gene expression profiles related to cell adhesion and calcium ion binding. These findings suggest that NNMT not only plays a pivotal role in ccRCC aggressiveness but also may serve as a valuable prognostic biomarker and a potential therapeutic target for improving clinical outcomes in patients with this malignancy.
- 1 October 2024
- Published by MDPI AG in Preprints.org
Open AccessExploring the Therapeutic Potential of Nicotinamide‐N‐Methyltransferase in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is a highly aggressive subtype of renal cancer, often associated with poor prognosis and high mortality rates. In this study, we identified Nicotinamide N-methyltransferase (NNMT) as a key gene involved in the pathogenesis of ccRCC through RNA sequencing analysis of tumor and normal tissues from 14 patients. NNMT was among the top five upregulated genes, and its high expression was significantly correlated with reduced overall, progression-free, and disease-specific survival in patients, as well as advanced pathological stages and higher histologic grades. Gene ontology (GO) enrichment analysis revealed NNMT's role in biological processes such as signal transduction and immune response. Immune cell infiltration analysis indicated that high NNMT expression was associated with increased infiltration of activated NK cells and macrophages, while low expression correlated with a higher presence of regulatory T cells. Functional studies using siRNA-mediated NNMT knockdown in ccRCC cell lines demonstrated a significant reduction in cell proliferation, with further analysis revealing altered gene expression profiles related to cell adhesion and calcium ion binding. These findings suggest that NNMT not only plays a pivotal role in ccRCC aggressiveness but also may serve as a valuable prognostic biomarker and a potential therapeutic target for improving clinical outcomes in patients with this malignancy.
- Open Access
Deciphering the Role of ERBB3 Isoforms in Renal Cell Carcinoma: A Comprehensive Genomic and Transcriptomic Analysis
ERBB3, a key member of the receptor tyrosine kinase family, is implicated in the progression and development of various human cancers, affecting cellular proliferation and survival. This study investigated the expression of ERBB3 isoforms in renal clear cell carcinoma (RCC), utilizing data from 538 patients from The Cancer Genome Atlas (TCGA) Firehose Legacy dataset. Employing the SUPPA2 tool, the activity of 10 ERBB3 isoforms was examined, revealing distinct expression patterns in RCC. Isoforms uc001sjg.3 and uc001sjh.3 were found to have reduced activity in tumor tissues, while uc010sqb.2 and uc001sjl.3 demonstrated increased activity. These variations in isoform expression correlate with patient survival and tumor aggressiveness, indicating their complex role in RCC. The study, further, utilizes CIBERSORTx to analyze the association between ERBB3 isoforms and immune cell profiles in the tumor microenvironment. Concurrently, Gene Set Enrichment Analysis (GSEA) was applied, establishing a strong link between elevated levels of ERBB3 isoforms and critical oncogenic pathways, including DNA repair and androgen response. RT-PCR analysis targeting the exon 21–23 and exon 23 regions of ERBB3 confirmed its heightened expression in tumor tissues, underscoring the significance of alternative splicing and exon utilization in cancer development. These findings elucidate the diverse impacts of ERBB3 isoforms on RCC, suggesting their potential as diagnostic markers and therapeutic targets. This study emphasizes the need for further exploration into the specific roles of these isoforms, which could inform more personalized and effective treatment modalities for renal clear cell carcinoma.
Open AccessDeciphering the Role of ERBB3 Isoforms in Renal Cell Carcinoma: A Comprehensive Genomic and Transcriptomic Analysis
ERBB3, a key member of the receptor tyrosine kinase family, is implicated in the progression and development of various human cancers, affecting cellular proliferation and survival. This study investigated the expression of ERBB3 isoforms in renal clear cell carcinoma (RCC), utilizing data from 538 patients from The Cancer Genome Atlas (TCGA) Firehose Legacy dataset. Employing the SUPPA2 tool, the activity of 10 ERBB3 isoforms was examined, revealing distinct expression patterns in RCC. Isoforms uc001sjg.3 and uc001sjh.3 were found to have reduced activity in tumor tissues, while uc010sqb.2 and uc001sjl.3 demonstrated increased activity. These variations in isoform expression correlate with patient survival and tumor aggressiveness, indicating their complex role in RCC. The study, further, utilizes CIBERSORTx to analyze the association between ERBB3 isoforms and immune cell profiles in the tumor microenvironment. Concurrently, Gene Set Enrichment Analysis (GSEA) was applied, establishing a strong link between elevated levels of ERBB3 isoforms and critical oncogenic pathways, including DNA repair and androgen response. RT-PCR analysis targeting the exon 21–23 and exon 23 regions of ERBB3 confirmed its heightened expression in tumor tissues, underscoring the significance of alternative splicing and exon utilization in cancer development. These findings elucidate the diverse impacts of ERBB3 isoforms on RCC, suggesting their potential as diagnostic markers and therapeutic targets. This study emphasizes the need for further exploration into the specific roles of these isoforms, which could inform more personalized and effective treatment modalities for renal clear cell carcinoma.